Day 1

Introductory remarks

Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer

Session 1 – Keynote presentation

Chair: Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer

  • The Quirks of EUCAST: what to consider when hoping for breakpoints for a new agent – from EUCAST and others
    • Professor Gunnar Kahlmeter, Professor of Clinical bacteriology & Head of the EUCAST Development Laboratory

Session 2 – Drug discovery: new targets and new chemistry

Chair: Professor Nathaniel Martin, Chair of Biological Chemistry, Leiden University

  • Discovery of semi-synthetic antibiotics and adjuvants
    • Professor Jayanta Haldar, Jawaharlal Nehru Centre for Advanced Research (JNCASR)
  • Genome mining pipelines and tools to guide the discovery of new antibiotics
    • Professor Nadine Ziemert, German Centre for Infection Research (DZIF)
  • AI to discover new antibiotics for Gram-negative bacteria
    • Dr Jon Stokes, McMaster University

Session 3 – Preclinical antimicrobial development

Chair: Dr François Franceschi, Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader, GARDP

  • Bugworks: New gyrase inhibitors
    • Dr Shahul Hameed, Bugworks Research Inc.
  • GangaGen: Klebicins
    • Mr Vivek Daniel Paul, GangaGen

Session 4 – Panel discussion 

Chair: Professor Evelina Tacconelli, Verona University Hospital & DZIF Clinical Research Unit, University of Tubingen

  • How useful/successful are the WHO Priority Pathogen lists at identifying future targets for Antimicrobial Discovery Programmes?
    • Professor Stephan Harbarth, Geneva University Hospitals
    • Dr Erin M Duffy, CARB-X
    • Dr Hatim Sati, WHO AMR Division

Day one closing remarks

Dr Alison Luckey, Senior Medical Lead, GARDP

Day 2

Introductory remarks

Dr Alison Luckey, GARDP

Session 5 – Clinical Development and Use of New agents

Chair: Dr Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK

  • Navigating the regulatory process for “niche” antibiotics – Lessons learned from a Pathogen-focused clinical development pathway
    • Dr John O’Donnell, Innoviva Specialty Therapeutics
  • Role of data platform in antibiotic clinical development
    • Professor Philippe Guérin, University of Oxford
  • Can we include assessment of risk of resistance in clinical trials for novel antibiotics?

Session 6 – Oral Poster Presentations

Chair: Dr Tom Ashfield, Pfizer Hospital Business Unit

  • Development of Novel Antibiotics Targeting Bacterial Transcription: Promising Antimicrobial Activity and Pharmacological Properties
    • Mr Cheuk Hei Kan, The Chinese University of Hong Kong, China
  • Oxiconazole Potentiates Gentamicin against Gentamicin-Resistant Staphylococcus aureus in vitro and in vivo
    • Mr Abdul Akhir, CSIR-Central Drug Research Institute, India
  • Unveiling Overlooked Critical Parameters in the Hollow Fiber System for Tuberculosis Studies: Impact on Moxifloxacin Pharmacokinetics/Pharmacodynamics
    • Dr Diana A. Aguilar Ayala, University of Zaragoza, Spain
  • Antimicrobial Chemotherapy in Neurological Disorders: A Call for Action in Low- and Middle-Income Countries (LMICs)
    • Dr M Faizan Siddqui, Osh State University, Kyrgyzstan & AIG Hospital, Asian Institute of Gastroenterology, India
  • Modified Carbapenem Inactivation Method (mCIM) as a tool of antibiotic stewardship for Gram negative bacteremia in Teaching Hospital Kandy
    • Dr Kaushila Dinithi Galgamuwa, National Hospital Kandy, Sri Lanka

Session 7 – Ensuring long-term security of access to new antimicrobials

Chair: Dr Jesús Rodríguez-Baño, Professor of Medicine, University of Seville & Head, Infectious Diseases Division, Hospital Universitario Virgen Macarena, Seville, Spain

  • Implementation of AMS strategy across a diverse nation(s)
    • Dr Abdul Ghafur, Apollo Hospitals, Chennai, India
  • Monitoring resistance and consumption of new antibiotics: who, how, when
    • Dr Dominique L Monnet, ARHAI & ECDC
  • Antimicrobial shortages/supply chain analysis
    • Dr Esmita Charani, University of Cape Town

Session 8 – Panel discussion: 

Chair: Dr François Franceschi, Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader, GARDP

  • Are existing push and pull incentives sufficient to strengthen the antibiotic R&D pipeline and ensure treatments reach patients?
    • Dr Lesley Ann Ogilvie, Global AMR R&D Hub
    • Mr Luka Srot, IFPMA
    • Dr Rohit Malpani, Advisor (consultant), GARDP

Closing remarks

Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer